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ABSTRACT 
Biofilms can be found in any environment within proximity to water and are problematic 
in an assortment of industries. Numerous efforts have been employed to dislodge biofilms 
including bacteriophages (viruses that infect bacteria). Phage remediation is a promising solution 
for combatting biofilms that form on catheters in long term use patients. These biofilms often 
result in catheter-associated urinary tract infections (CAUTIs) and are the most common type of 
healthcare related infection reported. Additionally, they result in longer hospital stays and 
increased morbidity. To date, most of the research on the topic focuses on single species 
biofilms, despite their rarity in nature. Here we assess the efficacy of five phages and a phage 
cocktail to treat both homogeneous as well as heterogeneous, multispecies biofilms. The effects 
of phage treatment were assessed looking at both the absorbance and colony counts of the 
biofilm as well as the planktonic fraction. Two phages, Greedy and phiKZ, had the greatest 
success in lysing bacterial cells and were thus selected for a phage cocktail treatment regimen. 
By evaluating the effects on both monoculture and heterogeneous biofilms, phage species can 
more accurately be assessed for their potential use in treating CAUTIs. 
 
1 
CHAPTER ONE 
 
INTRODUCTION 
Biofilms 
A biofilm is an aggregation of microbes and substrates from the surrounding environment that 
are encased in a microbe-produced complex polysaccharide matrix often adhered to a solid 
surface (see review Flemming et al. 2016). There are several phases of biofilm formation. First, a 
primer film composed of microbial and environmental molecules forms on the surface of the 
substrate (Chondki et al. 2011). Hydrophobic interactions either repel or attract microbes to the 
surface, in which attracted bacterial cells bind weakly to each other (see review Kaplan 2011). 
Next, in the growth phase, irreversible attachment occurs when the weak bonds are reinforced by 
stronger bonds to the cell wall or pili (Rosan and Lemont, 2000). In maturity, the initially 
attached bacteria attract other bacteria through means such as cell to cell communication through 
chemical signals (quorum sensing). This, in conjunction with cell multiplication and the 
secretion of polysaccharides (generating the matrix), results in organization of the biofilm and 
the shift from an aerobic environment to a facultative anaerobic environment. When the biofilm 
reaches a critical mass, the last phase in biofilm development occurs: dispersal; bacteria are 
dispersed into the environment to colonize new areas. Figure 1 illustrates this process. 
 The microbes within a biofilm differ from their counterparts in the liquid surrounding the 
biofilm (the planktonic fraction) in many ways. They may develop an altered phenotype, 
including different growth rates (see review Flemming et al. 2016) and transcription profiles 
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(see review Socransky and Haffajee, 2002). Additionally, communities within biofilms often 
display increased gene exchange rates and tolerance to antimicrobials (Flemming et al. 2016). 
The polysaccharide matrix provides channels useful for nutrient acquisition and chemical 
signaling (Flemming et al. 2016). It also provides physical protection of microbes deeper in the 
matrix. These altered properties are unique to biofilms and are thus unpredictable by typical 
liquid culture based studies (Flemming et al. 2016). These advantageous effects are compounded 
in multispecies (heterogeneous) biofilms when compared with single species (homogenous) 
biofilms. 
 
Figure 1. Five phases of biofilm development: (1) initial attachment, (2) irreversible attachment, 
(3) initial maturation, (4) later maturation, and (5) dispersion. 
 
Studies have shown that multispecies biofilms, in comparison to their single species 
counterparts, have increased mass and resistance to antimicrobials (Lee et al. 2014, Burmølle et 
al. 2014). Due to the microscopic matrix structure, members of the microbial community within 
a biofilm interact both physically and socially. These social interactions may be cooperative. For 
example, microbes within biofilms have been observed to share resistance to, e.g., 
antimicrobials, antibiotics, and toxins (Lee et al. 2014, Burmølle et al. 2014, Chandki et al. 
2011); often if a member of the biofilm community is resistant to an antibiotic, the entire 
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community becomes resistant. Instances of metabolic cooperation (syntrophy) have also been 
observed amongst microbes within biofilms (Lee et al. 2014, Ren et al. 2014). Alternatively, 
these microbial social interactions may be antagonistic such as producing chemicals toxic to 
other microbes and resource composition (Rao et al. 2005).  
Biofilms are a key constituent of the microbial world. They are ecologically important 
and can be found anywhere within proximity to water. Biofilms found on rocks in streams 
provide sustenance to bottom feeders, indicating their essential role in the food web of streams 
(see review Battin et al. 2016). They likewise have immediate benefits for human health. For 
instance, within the human microbiota, biofilms in the gut play an important role in degradation 
of substrates (de Vos 2015). Biofilms also benefit human health through their important role 
within the wastewater treatment process. In fact, three types of biofilms, distinguished by their 
structure, are typically included within this process: static biofilms, particulate biofilms, and 
flocs (see review Nicolella 2000). Research has found that the presence of a biofilm in the 
activated sludge stage of water treatment improves processing performance (Gebara 1999). Yet 
another industrial use of biofilms includes their potential applications for bioremediation, e.g. 
crude oil degradation (Dasgupta et al. 2013). Biofilm reactors have the potential to revolutionize 
production of biological materials (e.g. antibiotics) and even electricity (see recent review 
Todhanakasem 2016). While a few of the documented beneficial uses of biofilms are listed here, 
this is far from a comprehensive list.  
Despite the many ecological benefits of biofilms, they can also be detrimental. 
Problematic biofilms include, for example, those that form on the bottom on boats or in fuel 
tanks, food processing centers, municipal drinking water systems, or sewer systems in large 
cities (e.g. Drake et al. 2005, Hvitved-Jacobsen et al. 2013, Douterelo et al. 2016). Biofilms can 
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also be detrimental to human health (Macfarlane and Dillon 2007). In cystic fibrosis patients, P. 
aeruginosa biofilms form in the lungs and are extremely difficult to treat due to the protective 
nature of biofilms (Høiby et al. 2010). Biofilms that form on the teeth of animals and humans 
(plaque) cause periodontal disease (Chandki et al. 2011). Infection and biofilm formation within 
the human body can have severe and even lethal effects and is thus an important area of research 
within the biomedical community. 
Phage Therapy 
Given the many detrimental effects biofilms have on human health, strategies for combating their 
formation as well as their destruction are of critical importance. Biofilm treatment using 
bacteriophage (phage therapy) is a particularly promising approach. Bacteriophages or phages 
are viruses that infect bacteria; they are nature’s biological weapon against bacteria. Here we will 
briefly review the aspects of bacteriophage biology of relevance to our study and refer the reader 
to the many excellent available reviews, including Clokie et al. (2011), for further details about 
phages. When lytic phages encounter a bacterial cell host, they inject their DNA or RNA 
genome. Once inside the host, the phage replicate and eventually trigger the bacterial host cell to 
“burst.” Phage progeny are released with this burst to hunt new hosts (bacteria). This process, 
called lysis, has been found to play a significant role in bacterial death in several ecosystems 
(e.g. Berdjeb et al. 2011). 
 Bacteriophage remediation is also a promising approach as phages can be grown within 
the laboratory at minimal expense. In fact, some phages produce specific enzymes for the 
degradation of the polysaccharide matrix that is central to the stability of biofilms (Harper et al. 
2014). Moreover, phages typically have a narrow host range; they are often only capable of 
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successfully infecting and lysing a single bacterial species or strain. Thus, phages can be used to 
specifically target a bacterial infection with high efficacy (Koskella and Meaden 2013). 
Phage therapy, however, does raise reasonable concerns. For instance, when phage lyse 
(kill) bacteria, toxins may be released into the body and/or encoded by the phage itself (Loc-
Carrillo and Abedon 2011). Lysis also can lead to the rapid release of lipopolysaccharides from 
the bacterial cell wall that, when at high concentrations, can lead to cytokine cascades (Nilsson 
2014). Furthermore, phage treatment of internal organs, many of which are not natural 
environments for phages, has been shown to activate an immune response (Nilsson 2014). In 
targeting one biofilm, it is important to remember that the human body is composed of many 
beneficial bacteria that support health (see review Lloyd-Price et al. 2016). Thus, phage therapy 
may lead to subsequent infections or dysbiosis. 
In addition to these concerns, there are several challenges for phage therapy. First and 
foremost is the ability to administer phage treatment. As phage treatment would be most 
effective if introduced in close proximity to the bacterial infection, this is a hurdle when the area 
or organ being treated cannot be easily accessed. It is for this reason that phage therapy has been 
most successful for “easy-to-reach” infections, e.g. acne (Jonńczyk-Matysiak et al. 2017). The 
greatest obstacle facing the wide-spread adoption of phage therapy, however, is evolution itself. 
While phages can infect and kill bacteria, they are in a constant arms race with bacteria, which 
are continually evolving resistance to infection from phages (Dennehy 2012). This race is 
expedited by the short generation times of bacteria and phage. 
To combat this problem, research has focused on phage cocktails (combining multiple 
phages for treatment), and using phage treatment in combination with antibiotics or chemicals. 
One study found a cocktail of seven phages to be effective at inhibiting Staphylococcus aureus 
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biofilms (Kelly et al. 2012). The phage ΦPan70 was successful at treating Pseudomonas 
aeruginosa biofilms in mice with an animal survival of 80-100% (Holguin et al. 2015). Quorum 
sensing enzymes secreted by a modified T7 phage inhibited biofilm formation in heterotrophic 
Escherichia coli and P. aeruginosa biofilms (Pei and Lamas-Samanamud 2014). Two phages 
were used to reduce Campylobacter jejuni biofilms on glass slides; C. jejuni biofilms are 
problematic in the digestive tract and water pipes (Siringan et al. 2011). In the work of Chaundry 
et al. (2017), P. aeruginosa biofilms were more effectively treated with a combination of phage 
and antibiotics than either treatment alone. These are but a few studies exploring phage 
remediation of biofilms. The rise in antibiotic-resistant bacteria has impelled research efforts to 
identify phage species capable of combating a variety of common infections. 
Catheter-Associated Urinary Tract Infections 
Biofilms that form in long-term use urinary catheters are particularly problematic. These 
biofilms, if left untreated, can lead to catheter-associated urinary tract infections (CAUTIs). 
According to the Center for Disease Control and Prevention (CDC), CAUTIs are the number one 
urinary tract infection (UTI) contracted in the hospital (CDC 2017). Furthermore, per a March 
2016 CDC press release, one in ten CAUTIs are caused by urgent or serious antibiotic-resistant 
bacteria (CDC 2016). For this reason, much research has gone into CAUTI treatment and 
reducing the occurrence of CAUTIs (see reviews Siddiq and Darouiche 2012, Tenke et al. 2017). 
Chemical treatment of catheters with Triclosan (Jones et al. 2006), EDTA (Percival et al. 2009) 
or Fluorofamide (Morris and Stickler 1998) has yet to show a sufficient reduction in CAUTI 
cases. Investigations into other materials (glass, polystyrene, and plastics) used in catheter 
construction have unfortunately not produced a reduced incidence of CAUTIs (see review Tenke 
et al. 2017). Catheters fitted with silver electrodes were successful in decreasing the rate of 
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biofilm formation when electric currents were applied (Chakravarti et al. 2005). This study and a 
subsequent study (Voegele et al. 2015), however, have been limited to in vitro models. Of 
particular recent interest, the application of phages has also been explored for thwarting catheter-
associated biofilm formation and CAUTIs (see review Siddiq and Darouiche 2012) and will be 
discussed in greater depth in a subsequent subsection of this chapter. 
While several bacteria have been associated with CAUTIs, the most prevalent is Proteus 
mirabilis. P. mirabilis is a quorum sensing bacteria found in soil, water, and the digestive tracts 
of multiple animals. Quorum sensing (QS) bacteria send out chemical signals as a means of 
communicating with other members of its community, an ability which can be quite 
advantageous to the bacterium, particularly during biofilm formation. With P. mirabilis’ capacity 
for both swarming and swimming motility (Williams et al. 1978), coordination between the two 
processes is of particular interest (Rossman et al. 2015). Research has found that P. mirabilis can 
detect cues in the surrounding environment triggering its switch from swimming to swarming or 
vice versa (Armbruster et al. 2013). Swarming cues, including L-arginine, DL-histidine, L-
glutamine, malate, and DL-ornithine, are all present in normal human urine and can thus initiate 
the establishment of biofilms within catheters (Armbruster et al. 2013). Furthermore, P. mirabilis 
is also able to form crystalline biofilms as a result of urease activity, which in humans can result 
in the occurrence of CAUTIs (Mobley and Warren 1987, Stickler et al. 1993, Holling et al. 
2014). 
Other common species associated with CAUTIs include Pseudomonas aeruginosa, 
Escherichia coli, Klebsiella pneumoniae, Serratia marcesens, and Morganella morganii (Gravey 
et al. 2017). Herein we will focus on just two of these taxa as they are amongst the best studied 
in microbiology: P. aeruginosa and E. coli. Like P. mirabilis, P. aeruginosa is a QS bacterium. 
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It is commonly found in the skin flora, soil, and water. P. aeruginosa is also an opportunistic 
human pathogen associated with pulmonary infections, particularly in cystic fibrosis patients, as 
well as infections of burn wounds and chronic wounds (Mulcahy et al. 2014). P. aeruginosa 
utilizes its unipolar flagella for swarming and swimming motility. Additionally, P. aeruginosa 
siderophore activity could have an important effect on community structure and dynamics within 
a biofilm (Cornelis and Dingemans 2013). The second bacterium of interest is E. coli, which can 
also be a constituent of catheter biofilms and is the most common cause of UTIs (Hooton et al. 
2010). E. coli, while non-quorum sensing, utilizes its type I pili for biofilm initial attachment and 
potentially the spread of biofilm growth across a solid surface (Pratt and Kolter 1998).  Efficient 
biofilm formation has been observed for E. coli species in environments replicating the bladder 
and catheters (Azevedo et al. 2014). 
Bacteriophages of the Urinary Microbiota 
In many areas of the human microbiome, most notably the gut (Manrique et al. 2017), overall 
microbial community structure is largely dictated by phages. Changes in the “native” human 
virome (viral community - both eukaryotic viruses that infect human cells and phages) have been 
associated with diseases and perturbations, e.g. inflammatory bowel (Norman et al. 2015, 
Manrique et al. 2016), periodontal disease (Ly et al. 2014), and the spread of antibiotic 
resistance (Modi et al. 2013), among others. Phages are also present within the microbiota of the 
bladder. Sequencing of voided urine from individuals with and without a UTI revealed the 
urinary virome (Santiago-Rodriguez et al. 2015). Similar to that observed within the gut 
microbiota, the urinary virome study found that phages vastly outnumber eukaryotic viruses in 
the urinary virome (Santiago-Rodriguez et al. 2015). In addition to phage detection via large-
scale whole genome sequencing efforts (Rani et al. 2016, Santiago-Rodriguez et al. 2015), phage 
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species have been isolated directly from the urinary microbiota and characterized in the lab, 
including seven isolated in the Putonti lab (Malki et al. 2016). 
In contrast with other areas of the human microbiome, the bacteria and phages present 
within the bladder are just now beginning to be explored. It was long believed that the urinary 
tract of healthy (asymptomatic) individuals was sterile. It was for this reason that during the 
Human Microbiome Project, which cataloged the bacterial species present within the human 
body, the bladder was omitted. This longstanding belief, however, was overturned when the 
bladder was found to include a variety of bacterial species (Wolfe et al. 2012). Prior work in the 
Putonti lab found that latent (dormant) phages are prevalent within bacterial species from the 
female bladder. Analysis of the genomes of over 200 bacteria isolated from the female urinary 
microbiota has found >80% harbor phage sequences (Miller-Ensminger et al., unpublished). This 
initial work and focused studies on bacterial strains from the bladder (Malki et al. 2015) suggests 
that phages are highly prevalent within the urinary microbiota. Details regarding phage host 
range and the role that phages play in shaping the bacterial populations within the bladder, 
however, have yet to be determined. 
Phage Therapy for Catheter-Associated Biofilms 
The use of phage treatment to inhibit and reduce biofilm formation began in 2006 when Curtin 
and Donlan showed that Bacteriophage 456 could be used to treat catheter-associated 
Staphylococcus epidermis biofilms (Curtin and Donlan 2006). Several phages were found to be 
90% effective in disrupting the formation of homogenous E. coli and P. mirabilis biofilms in 
comparison to untreated controls (Carson et al. 2010). With the development of a catheter model 
system, phage M4 and four other phages were tested to treat P. aeruginosa biofilms (Fu et al. 
2010). While a P. aeruginosa colony resistant to all five phages was uncovered, it had a reduced 
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growth rate (Fu et al. 2010). The bacteriophage T7 was also found to be successful in inhibiting 
biofilm formation of more complex communities including both E. coli and P. aeruginosa (Pei 
and Lamas-Samanamud 2014). Similarly, phage capable of inhibiting biofilm formation for other 
pairs of CAUTI-associated bacteria have been studied (Lehman and Donlan 2015). 
 One avenue of phage therapy specific to catheter-associated biofilm formation is the 
potential to pretreat catheters with specific phage(s). For instance, catheters pretreated with a 
phage cocktail showed inhibition of P. aeruginosa biofilm growth; this success, however, was 
short-lived as P. aeruginosa biofilm growth resumed at 24 hrs post-treatment (Fu et al. 2010). 
Other studies have been more successful. For example, two phages were used to treat catheters 
and showed significant reduction of P. mirabilis biofilms for up to 168 hrs after treatment (Melo 
et al. 2016). In another study, catheters were pretreated with a “benign” strain of E. coli and 
phage to successfully inhibit biofilm formation (Liao et al. 2012). 
 Prior research in phage therapy for catheter-associated biofilms has routinely found that 
the timing of phage treatment is vital to its effectiveness. While pretreatment of catheters with 
phage can inhibit biofilm formation, phage treatment of established biofilms has been less 
effective. While it may delay biofilm growth, as one study found, catheter blockage is often 
inevitable (Nzakizwanayo et al. 2015). Further testing of phages is thus needed to determine the 
viability of a phage therapy solution for the prevention and treatment of biofilms within catheters 
and resulting CAUTIs. 
Specific Aims 
While prior research exploring phage therapy for catheter-associated biofilms has largely 
focused on homogenous biofilms in the laboratory, biofilms from patients with CAUTIs can be 
significantly more complex, i.e. include multiple species (Saint and Chenoweth 2003). Thus, 
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phage therapies capable of disturbing complex biofilm communities, have a greater potential to 
reduce infection rates in patients. My study explores the efficacy of phage treatment on the 
biofilms of three bacteria commonly associated with catheter biofilms (P. mirabilis, E. coli, and 
P. aeruginosa), investigating both homogeneous (monoculture) biofilms as well as heterogenous 
(multispecies) biofilms. To the best of our knowledge, this is the first study considering phage 
therapy for three species biofilms of catheter-associated bacteria. 
 This work is aimed at answer three questions. First, which phage(s) reduce biofilms? 
Second, how does phage treatment affect bacterial growth and community dynamics? Third, how 
does phage treatment affect bacterial phage resistance? 
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CHAPTER TWO 
 
METHODS 
Bacteria and Bacteriophage Strains 
Three bacterial species were used in this study: Proteus mirabilis CDC PR 14, Pseudomonas 
aeruginosa 1C, and Escherichia coli C. P. mirabilis and P. aeruginosa were obtained from the 
American Type Culture Collection, strains ATCC 29906 and ATCC 15692, respectively. E. coli 
C was obtained from Dr. Christina Burch (University of North Carolina Chapel-Hill). Each 
bacterium was propagated in liquid culture using LB (10.0 g/L tryptone, 5.0 g/L yeast, 10.0 g/L 
NaCl). Liquid cultures were grown at 37°C in a shaking (200 rpm) incubator.  
 Bacteriophages used in this study are listed in Table 1. Bacteriophages Habibi, Greedy, 
and Lust were isolated by our lab and have been described previously in the literature (Malki et 
al. 2015; Malki et al. 2016). Bacteriophage phiKZ was obtained from the Felix d’Herelle 
Reference Center for Bacterial Viruses (Quebec, Canada), strain designation HER153. DMS3 
was obtained from the O’Toole Lab (Dartmouth University). As shown in Table 1, the phages 
utilized in this study vary in their natural habitat as well as host range. Habibi and phiKZ both 
belong to the family of viruses Myoviridae. This family of viruses are characterized by their 
contractile tail sheath (Maniloff and Ackermann, 1998). PhiKZ is one of the largest documented 
members of this family (Herdtvelt et al. 2005), as most Myovirdae phages have genome sizes on 
par with that of Habibi. Greedy, Lust, and DMS3 are Siphoviridae phages. In contrast to 
Myoviridae, Siphoviridae viruses have long, noncontractile tails (Maniloff and Ackermann,  
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1998). The phages Greedy and Lust were both isolated from the urinary microbiota (Malki et al. 
2016) and thus have particular relevance to the study conducted here. Figure 2 shows electron 
microscope images for the five phage species. 
Phage Origin Host Family Genome Size GC% 
Habibi Lake Michigan E. coli & P. aeruginosa Myoviridae 65.73 kbp 54.9 
Greedy Bladder Isolate E. coli  Siphoviridae 60.04 kbp 44.6 
Lust  Bladder Isolate E. coli  Siphoviridae 41.94 kbp 54.5 
phiKZ Sewage P. aeruginosa Myoviridae 280.30 kbp 36.8 
DMS3 Clinical isolate P. aeruginosa Siphoviridae 36.42 kbp  64.3 
Table 1. A summary of information about the five phages used in this study. 
 
Figure 2. Images of the phages used in this study. (A) Habibi (Malki et al. 2015), (B) phiKZ 
(Fokine et al. 2007), (C) Greedy (K. Malki, unpublished data), (D) DMS3 (Budzik et al. 2004), 
and (E) Lust (K. Malki, unpublished data). 
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Growth Curves 
Growth curves were conducted to determine the exponential growth phase of the bacteria. This 
knowledge is useful in deciding the opportune time to inoculate cultures with phage in isolation 
attempts. Furthermore, the growth curve enables us to estimate the number of bacterial colonies 
in a culture at a given time point, this is used to ascertain the appropriate phage concentration to 
use in treatments. Prior to this study our lab performed growth curves for E. coli and P. 
aeruginosa (unpublished data) which were referenced for those cultures. 
 To generate the growth curve for P. mirabilis, a single colony was used to inoculate a 50 
mL flask of LB and glass beads, the culture was then grown for 21 hrs. 100 µl was used to 
subculture three flasks containing 300 mL of LB and glass beads. The glass beads were added to 
the culture to minimize biofilm formation. Three mL aliquots were taken from each replicate 
every 15 mins for that first 90 mins after inoculation. Samples were then taken every half-hour or 
hourly for 17.5 hrs post-inoculation. Additional samples were collected at 25 and 33.5 hrs to 
capture the stationary phase of growth. In total, 32 samples were collected. From the 3 mL 
sample collected, 2 mL was placed immediately on ice until plating/storage and 1 mL was 
assayed via the spectrophotometer. Readings were taken at 660 nm and 750 nm. For plating, 8-
fold serial dilutions were performed; 100 µl of the aliquot was serially diluted into 1 mL of LB 
eight times, thus reducing the number of bacterial cells with each dilution by 1:10. For each 
dilution, 100 µl was spread on an LB plate using a sterile spreader. Plates were subsequently 
placed in a non-shaking 37°C incubator overnight. Colonies were counted the following day or 
replated if necessary. Figure 3 shows the growth curve produced, the first growth curve of P.  
mirabilis CDC PR 14 to our knowledge.  
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Figure 3. P. mirabilis growth curve. Standard deviation error bars are shown for the three 
replicates. 
 
Biofilm Selection Experiment 
A single colony of P. mirabilis, E. coli, or P. aeruginosa was added to 20 mL of LB within a 50 
mL capped centrifuge tube containing a sterile microscope glass slide. After overnight growth at 
37°C in a 200 rpm shaking incubator, a sterile loop was used to sample from the center of the 
biofilm formed on the slide. This sample was then used to inoculate 20 mL of LB, again within a 
50 mL capped centrifuge tube containing a microscope glass slide. Samples from these biofilms 
were also streaked on an LB plate or low-salt LB (LSLB) (0.5 NaCl g/L) plate (LSLB plates 
reduce P. mirabilis swarming), to ensure contamination had not occurred. The following 
protocol was conducted for up to 19 passages. By selecting only bacteria which successfully 
biofilmed to propagate subsequent populations, this experimental protocol selected for strains 
that were efficient in forming biofilms. The passages were continued until a visible biofilm was 
established and could be reproduced from a single colony selected from the streaked bacterium. 
Images of representative biofilms are shown in Figure 4. 
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Figure 4. Biofilm formation on glass slides. Images are from left to right P. aeruginosa, P. 
mirabilis and E. coli. 
 
Phage Growth and Titration 
Each phage was plated from our lab’s freezer stock and validated for uniform plaque 
morphology. A single plaque was harvested such that all subsequent work was derived from a 
single genotype. To harvest phage, a 1000 µl pipette tip was used to puncture the agar around the 
plaque and then transferred to a microcentrifuge tube containing 1000 µl of LB. The tubes were 
then vortexed for 10 mins using the Disruptor Genie vortex (Scientific Industries). Next, tubes 
were centrifuged at 10,000xg for 1 min and the lysate was transferred to a fresh microcentrifuge 
tube. Samples were chloroformed (1-2% by volume) and tubes were vortexed for 10 secs. Prior 
to transferring the lysate, samples were centrifuged again as described previously. Lysates were 
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then spotted on their respective bacterial hosts using the double layer agar method, in which a 
1.7% agar LB plate was overlaid by 3 mL of 0.7% agar LB (LBSA) mixed with 1 mL of 
bacterial culture. These plates were then grown overnight at 37°C in a non-shaking incubator. 
Phage plaques were scraped off of the agar with a sterilized scoopula, transferred to a 
microcentrifuge tube containing 1000 µl of LB, chloroformed, vortexed and centrifuged. 
 An 8-fold dilution of the lysate was then performed and plated to determine phage titer. 
For dilutions: 100 µl of phage harvest was aliquoted into 1 mL of LB. A stepwise dilution was 
conducted, reducing the phage population with each transfer by 1:10. Lust, Greedy, phiKZ, and 
DMS3 were grown, harvested, and plated until plaques were visible at 10-8. The titers of Lust 
and Greedy were increased through growth on their host E. coli while the titers of phiKZ and 
DMS3 were increased through growth on their host P. aeruginosa. Habibi was propagated until 
plaques were visible at 10-7 dilution on P. aeruginosa and 10-5 dilution on E. coli. In order to 
retain Habibi’s ability to successfully lyse both P. aeruginosa and E. coli, culture in both 
bacterial species was necessary. Titers for all five phages were confirmed via a pour plate in 
triplicate in which two consecutive dilutions were plated. Pour plates were produced as follows: 
100 µl of the appropriate dilution was added to 1 mL of the phages host and placed on the 
benchtop for 10 mins before adding 3 mL of 50°C LBSA. This mixture was then poured over an 
1.7% agar LB plate. After setting, plates were placed in a 37°C non-shaking incubator and 
allowed to grow overnight. Plaques were then counted. 
Biofilm Experimental Design 
The experimental design is depicted in Figure 5. Briefly, 20 mL of LB was added to a 50 mL 
capped centrifuge tube in addition to a sterile microscope glass slide. Glass slides were sterilized 
by submerging them in 70% EtOH after which they were placed in a sterile hood overnight for 
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EtOH evaporation. Each tube was inoculated with a single colony of the bacterial species. (When 
more than one bacterial species was used to form a biofilm, the culture was inoculated 
simultaneously with a single colony from each species.) The tube was incubated at 37°C, 
shaking at 200 rpm. After a 24-hr incubation, the glass slide was removed with sterile forceps. 
Excess liquid was removed from the bottom of the slides with a Kimwipe, and the slides were 
placed into new 50 mL tubes with 20 mL of fresh LB. Each slide was then treated with phage (or 
no phage in the case of the control). The 24 hr time point was chosen because after a day 
organization of bacterial species and the matrix has taken place and is truly considered a biofilm 
(Chandki et al. 2011). Following treatment, tubes were returned to the incubator and allowed to 
grow for an additional 24 hrs at 37°C, shaking at 200 rpm. Next the glass slides and a portion of 
the planktonic fraction were removed for further analysis. 
 
Figure 5. A visualization of the experimental design including biofilm growth and treatment. (1) 
Empty sterile 50 mL centrifuge tube. (2) 20 mL of LB and (3) a sterile glass slide was placed in 
the tube. A single bacterial colony per species is added and allowed to grow for 24 hrs resulting 
in biofilm formation (4). (5) The glass slide was removed and placed into a centrifuge tube 
containing fresh LB. Treatment was then applied to the slide and placed in the incubator for an 
additional 24 hours. (6) The slide and planktonic fraction from the tube is separated for 
subsequent analyses. 
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 For Greedy, Lust, phiKZ, and DMS3 treatments, 100 µl of phage (~106 phage/µl) was 
added to 200 µl of phosphate buffered saline (PBS) (8 g/L NaCl, 0. 2g/L KCl, 1.44 g/L 
Na2HPO4, and 0.24 g/L KH2PO4, adjusted to pH=7). For Habibi treatments, 100 µl of phage 
(~105 phage/µl in P. aeruginosa and ~103 phage/µl in E. coli) was added to 200 µl of PBS. The 
decreased titer of Habibi was used to remain consistent in treatment volumes and because of 
Habibi’s unique ability to infect and lyse two potential members of the biofilm. 
 All combinations of the three bacteria received each individual phage treatment in 
addition to no treatment (PBS) in triplicate. E. coli, P. aeruginosa, and E. coli + P. aeruginosa 
(EP) biofilms also received a phage cocktail treatment consisting of phiKZ and Greedy. The 
cocktail treatments included 50 µl of each phage (~106 phage/µl) in 200 µl of PBS. Alongside 
each set of biofilm samples, a forth biofilm was also grown to check for contamination of slides, 
LB, and/or PBS. Serving as a negative control, these samples were not inoculated with any 
bacterial species and were treated with 300 µl PBS at the 24 hr mark. Figure 6 lists the 
treatments conducted. 
Mass 
Biofilm formation and effects of phage treatment were evaluated based upon the mass of the 
biofilm. Dry weights of 1.5 mL microcentrifuge tubes were recorded using a scale. One mL of 
sterile LB broth was added and weight was again recorded. For biofilms: glass slides were 
removed from 50 mL centrifuge tubes using sterile forceps, the bottom of the slide was touched a 
Kimwipe to remove excess liquid, and the established biofilm was scraped off of both sides of 
the slide using inoculating loops and placed into the LB containing microcentrifuge tubes. All 
tubes were subsequently vortexed and weighed. For the planktonic fraction: tubes containing LB 
were centrifuged and LB was removed and replaced by 1 mL of the planktonic fraction from 
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biofilm samples. Dry weights and LB weights were subtracted from final weights to obtain the 
mass of the biofilm and planktonic fraction. 
 
 
Figure 6. An image depicting biofilms generated and the treatments which were applied to them. 
The phage cartoon indicates that phage treatment was applied and a water droplet represents PBS 
treatment (control). All treatments for biofilms were conducted in triplicate. Biofilm cultures are 
abbreviated according to the bacteria used in the culture as follows. E=E. coli; P=P. aeruginosa; 
M=P. mirabilis; EP=E. coli and P. aeruginosa; EM=E. coli and P. mirabilis; PM=P. aeruginosa 
and P. mirabilis; and EPM=E. coli, P. aeruginosa, and P. mirabilis. Biofilms and the planktonic 
fraction were analyzed via absorbance, colony counting and host range.  
 
 
21 
 
 
Spectrometry and Colony Counting 
All spectrometry readings were done at 660 nm; blanks consisted of 1 mL LB broth. For the 
planktonic fraction, 1 mL was removed from the sample following 48 hrs of growth, vortexed for 
10 secs, aliquoted into a cuvette, and the absorbance was recorded. Resuspended biofilms from 
the mass reading were vortexed for 10 secs, removed from the microcentrifuge tube, and 
aliquoted into a cuvette and the absorbance was recorded. After recording the absorbance, each 
sample was returned to its original microcentrifuge tube for further analysis. For colony counts, 
100 µl of the resuspended biofilm or planktonic fraction was used to perform an 8-fold serial 
dilution as described previously. Two dilutions were plated for each sample; 100 µl of the 
dilution was aliquoted onto an LB plate or a low-salt LB (LSLB) (0.5 NaCl g/L) plate, spread 
using a sterilized spreader, and allowed to dry. The plate was then incubated at 37°C overnight. 
Colonies were counted for each plate and recorded. For samples inoculated by more than one 
bacteria, counts were determined for each individual species as identified visually via colony 
morphology and color. Plates were stored at 4°C. 
Bacterial Resistance Assay 
LSLB and LB plates were prepared for assessing the phage sensitivity of bacterial isolates from 
untreated and treated biofilms; LSLB plates were used to test P. mirabilis isolates and LB plates 
were used to test E. coli and P. aeruginosa isolates. Regardless of the bacterial species or phage 
being examined, plates were prepared as follows: 50 µl of naïve phage lysate was spread down 
the center of the plate and allowed to dry. From the plates produced for colony counting, three 
random colonies were picked for each species and streaked across the prepared plate, across the 
region containing the phage lysate. The plates were then incubated overnight at 37°C. Figure 7 
presents a representation of the results observed. If the bacterial growth was consistent through 
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the phage treated portion of the plate, it was considered resistant (Figure 7A). Bacterial growth 
that stopped at the beginning of the phage treated portion of the plate was considered sensitive 
(Figure 7B). Variation between resistant and sensitive growth was considered partially resistant 
(Figure 7C). As a control, an additional colony was streaked through an area of the plate 
containing no phage treatment (Figure 7D).  
 
Figure 7. Generalized visualization of method for determining resistance categories: (A) 
resistance to phage infection (B) susceptibility, (C) partial resistance, and (D) negative control. 
Green lines represent bacterial growth. Phage treatment was applied in the black box containing 
A-C. No phage was applied to the black box containing streak (D). 
 
Phage Identification 
Phage specific primers were designed using primer3 (Untergasser et al. 2012) for all phages as 
well as the documented prophage within the P. aeruginosa strain used in this study. For primer 
design, the genomes of each of the five phages were retrieved from NCBI. To determine the 
prophage sequence, we used PHASTER (Arndt et al. 2016, Zhou et al. 2011). The primers 
designed are listed in Table 2. All primer pairs were checked for self-priming and dimerization 
using the ThermoFisher Scientific Multiple Primer Analyzer (ThermoFisher Scientific 2017). 
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Additionally, all primer pairs were checked for specific amplification computationally by 
querying each sequence via BLASTX against the nr/nt collection, and at the bench via PCR 
against DNA from each other phage and each bacterial host. 
Phage Primers Amplicon Size Targeted Region 
Lust 
(KX534338) 
GATGCGCAAGGAGTTAGAGC 
ACGTGACACTCGCTTCACAC 
873 bp DNA methylase 
Greedy 
(KX534337) 
TGCTAGTGGCCAGCATAGTG 
TTGTAGAAGTGCAGCCGATG 
758 bp hypothetical 
protein 
Habibi 
(KT254132) 
ACCGACTCACGACGATGG 
CGGCAAGGTGTTCGCTTA 
904 bp putative structural 
protein 
DMS3 
(NC_008717) 
AACCGAACCTGAAAATGAC 
ATCCAAGTCAGAAAGCTGGT 
625bp putative C 
repressor 
phiKZ 
(NC_004629) 
CACGCGTGTAATCAAGACC 
CCTACTCGTTGGCCAAGTC 
964 bp structural head 
protein 
P. aeruginosa 
prophage 
(NZ_CP017149) 
GTGGAGCCAGAGTTTTACTG 
ATAGCGTAGGGAAAGGAATC 
527 bp annotated 
prophage 
Table 2. Primers used for the amplification of phage species. Accession numbers are listed for the 
genome sequences used to design the primers. 
 
 The PCR primers designed here were tested against genomic DNA extracted for each of 
the phages used in this study and for the P. aeruginosa genome (for the detection of the prophage 
sequence). PCR set up was as follows: 25 µl Ready PCR mix 2x (Amresco LLC), 0.5-1 µl 
forward primer, 0.5-1 µl reverse primer, 0.5-3 µl template, 20-23.5 µl nuclease free water. 
Thermocycler conditions for each phage tested are listed in Table 3. It is worth noting that this 
table does not include thermalcycling conditions for the identification of phiKZ. Attempts at 
phiKZ-specific PCR were unsuccessful due to insufficient phage concentration. Other phiKZ 
primers in our collection were also tested (results not shown) but were not successful in 
producing visible amplicons either. To identify phiKZ, plaques were tested against the prophage 
primers, in the event of no amplification, phiKZ was assumed.  
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Phage 
Initial 
Denature Denature Annealing Extension # cycles 
Final 
extension 
Greedy and 
Lust 
94°C 
10 mins 
94°C 
30 secs 
55.5°C 
45 secs 
72°C 
1 min 
30 72°C 
5 mins 
Habibi 94°C 
15 mins 
94°C 
30 secs 
52°C  
45 secs 
72°C 
45 secs 
45 72°C 
5 mins 
DMS3 94°C 
15 mins 
94°C 
30 secs 
54°C 
45 secs 
72°C 
45 secs 
30 72°C 
5 minutes 
P. aeruginosa 
prophage 
94°C 
10 mins 
94°C 
30 secs 
55°C 
30 secs 
68°C 
30 secs 
30 68°C 
5 mins 
Table 3. Thermocycler conditions for phage identity testing. 
 
 Planktonic and biofilm samples were chloroformed (2% by volume), vortexed for 10 
secs, and lysate was separated from the pellet. Subsequently, an 8-fold dilution was performed 
using 100 µl of serially diluted lysate. Dilutions were spotted onto naïve lawns of each bacterial 
species present in the biofilm. If lysis was observed after overnight growth, pour plates at the 
corresponding dilutions were performed. Ten random plaques were harvested from each plate as 
previously described (section “Phage Growth and Titration”). Plaque harvests were stored at 
4°C. 
 To identify the phage(s) producing the observed plaques, 50 µl of phage lysate was used 
to inoculate 1 mL of a naïve culture of the bacterial host, the bacterium on which the phage was 
harvested. Following overnight growth each sample was chloroformed (20 µl), vortexed, 
centrifuged (16,100xg rpm for 2 mins) twice, and the lysate was transferred to a sterile 
microcentrifuge tube. PCR reactions were immediately performed following the phage-specific 
protocol listed in Table 3. For positive controls 1 µl DNA was used. For PCR reactions of the 
samples, 3 µl of lysate was used. Amplicons were visualized using a 1.2% agarose gel. 
 If phage lysate PCR was unsuccessful, 10 µl of the phage lysate was plated using the 
double layer agar method previously described. Following overnight growth at 37°C, spots were 
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harvested and suspended in 300 µl nuclease-free H2O. This suspension was vortexed for 10 
mins, chloroformed (20 µl), vortexed 10 secs, and centrifuged at 16.1 rpm for 2 mins. Each 
sample was chloroform treated three times to ensure no viable host cells remained. Lysate was 
removed, separated from the pellet, and used as the sample input for PCR. If this PCR was 
unsuccessful, lysate was regrown as previously described and phage DNA was extracted using 
the UltraClean® Microbial DNA Isolation Kit (Mo Bio Laboratories). The manufacturer’s 
protocol was followed with the following exceptions: rather than pelleting down the sample for 
bacterial extraction, 300 µl of viral lysate was used with 250 µl of bead solution. Furthermore, a 
70°C heat step was added to increase DNA yield.  
Phage Host Range Assay 
Phage host range was tested in triplicate before experimental treatment. To test, 10 µl of pure 
phage cultures were spotted on bacterial lawns, allowed to dry, and incubated overnight at 37°C. 
To reduce the risk of contamination, spotting was limited to a single phage per plate. For phages 
that were able to infect multiple hosts, dilutions were plated so that individual plaques could be 
harvested. Single plaque harvests were subsequently used to confirm that plaques on multiple 
species were in fact the same phage. Post experimental host range was recorded using phage 
identification results.  
Statistical Analysis 
Statistical analyses were performed in R (R core Team 2013). Data for each biofilm was 
considered separately. For example, data collected for all of the 18 E. coli biofilm absorbance 
data points were considered and checked for normality using the shapiro.test function before and 
after any necessary transformations. Abnormally distributed data was log transformed, if the 
transformation failed to normalize the data a box-cox transformation was performed using the 
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bctransform function in the MASS (Venables and Ripley, 2002) package. If normalization was 
successful, a one way ANOVA was performed using the aov. function in the Rcmdr package 
(Fox and Bouchet-Valat, 2017; Fox 2017; Fox 2005). If the ANOVA resulted in a significant 
difference between treatments, a Tukey’s multiple comparison test was performed using the 
TukeyHSD function to identify which treatments were significantly different from each other.  If 
data could not be normalized the Kruskal.test function was used.  
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CHAPTER THREE 
 
RESULTS AND DISCUSSION 
Five phage species were selected for this study and are described in detail in the Methods and 
Table 1. Briefly, bacteriophage Greedy and Lust, both isolated from the microbiota of the human 
bladder (Malki et al. 2016), can effectively infect and lyse several E. coli strains including E. coli 
C. The bacteriophage phiKZ, isolated from sewage (Krylov et al. 1978), and DMS3, induced 
from P. aeruginosa clinical isolates (Budzik et al. 2004), are both capable of infecting and lysing 
P. aeruginosa including several human pathogenic strains of P. aeruginosa (Mesyanzhinov et al. 
2002). The fifth phage selected for this study is bacteriophage Habibi, which was isolated from 
Lake Michigan nearshore waters and is capable of infecting both E. coli and P. aeruginosa 
strains, amongst other bacterial taxa (Malki et al. 2015). Habibi is considered a broad host range 
phage, as it is capable of infecting across genera, while the other four phages used in this study 
are narrow host range phage, capable of infecting only strains of the same species. 
 Thus, our study includes phage species capable of infecting two of the bacterial species 
frequently associated with biofilms within catheters and CAUTIs. None of the phages, however, 
can infect the CAUTI-associated bacterium P. mirabilis. Although significant efforts were made 
to isolate a phage capable of reliably infecting and lysing P. mirabilis, we were unable to isolate 
a phage that could work consistently under standard laboratory conditions (results not shown). 
Furthermore, our attempt to purchase a P. mirabilis-infecting phage from the Felix d’Herelle 
Reference Center for Bacterial Viruses (Quebec, Canada) was also unsuccessful; the curators 
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were unable to propagate the one P. mirabilis phage in their collection. 
Effects of Phage Treatment on Homogeneous Biofilms 
Biofilms of E. coli, P. aeruginosa, and P. mirabilis were first treated by each of the five phage 
strains. As detailed within the Methods chapter, phage treatment was administered after the 
biofilm was established. Thus, our evaluation is focused on the effectiveness of phage treatment 
in reducing/eradicating biofilms. Furthermore, each of the bacterial strains used in this study 
were the result of a selection experiment in which bacterial colonies that were efficient in their 
ability to form biofilms were passaged serially (see Methods). Each treatment was conducted in 
triplicate along with a control (no treatment). After treatment of each of the three homogeneous 
biofilms, the efficacy of phage treatment was measured based on the biofilm’s absorbance and 
individual species colony counts. While the former captures the presence of both viable and non-
viable bacteria, the latter more closely represents the viable cells within the biofilm post-
treatment. We also measured the mass of the biofilm before and after treatment, but found these 
measurements to be unreliable as often biomass differences were not detected due to the lack of 
precision available by our nanoscale. We thus do not include these measurements in our 
discussions here. All boxplots shown represent untransformed data. 
 To ascertain the effectiveness of the five phages under investigation, we first examined 
the treatment of monoculture biofilms of E. coli and P. aeruginosa. Statistically significant 
effects were evaluated through the comparison of the biofilm density (absorbance or colony 
counts) of untreated biofilms (control) and the treated biofilms. Figure 8 depicts boxplots of 
absorbance and colony count data for E. coli and P. aeruginosa biofilms. Figures 8A and 8B 
show the absorbance and E. coli colony counts, respectively, for the control lines (untreated) as 
well as the treatments using Lust, Greedy, and Habibi. E. coli absorbance data was log 
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transformed and an ANOVA was performed (F3,8=9.792 P=0.0047). We found that treatments 
with the phages Lust (P=0.02597) and Greedy (P=0.00427) were significantly different from the 
control treatment when considering the absorbance (Figure 8A). However, treatment with Lust 
was not found to be significant when considering the colony count data. As shown in Figure 8B, 
the number of viable E. coli colonies (log-transformed) retrieved from the biofilm after treatment 
with Lust was highly variable. Nevertheless, Greedy (P=0.00919) was significantly different 
from control treatments for colony count data (F3,8=7.279 P=0.0113) (Figure 8B). 
 Figure 8C shows the measured absorbance from the untreated (control) P. aeruginosa 
biofilms as well as those treated by the phages phiKZ, DMS3, and Habibi. Statistical methods 
similar to that described for the absorbance data for the E. coli biofilms were conducted. No 
significant differences between the control and the treatments were identified (Figure 8C). We 
observed, however, that both phiKZ (P=0.00254) and DMS3 (P=0.04907) treatments resulted in 
statistically significant differences from the untreated control biofilms (Figure 8D). This was 
determined by performing box-cox normalization (lambda= -0.34) for the colony count data and 
an ANOVA (F3,8=10.1 P=0.00427). 
 From the results of these assays, we found that Greedy and phiKZ are the most effective 
at reducing biofilms of E. coli and P. aeruginosa, respectively (Figure 8). Quantifying the effects 
of biofilm treatment via both absorbance and colony counts provides a means of distinguishing 
between viable and inviable biofilms. For instance, the success of phiKZ treatment on the P. 
aeruginosa biofilm was not significant for the absorbance data (Figure 8C); it was, however, 
significant for the colony count data (Figure 8D). Thus, we believe that the colony count data 
provides a more robust measure of the effect of phage treatment of biofilms. 
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Figure 8. Effects of coliphage and P. aeruginosa phage treatments on homogenous E. coli and 
P. aeruginosa biofilms measured by absorbance (panels A and C) and colony counts (panels B 
and D). An asterisk denotes a statistically significant difference by Tukey’s multiple comparison 
test where * indicates a P-value < 0.05 and ** denotes a P-value < 0.01. 
 
 To date, the method by which Greedy and Lust infect the E. coli C cell is unknown. 
While a handful of coliphages exhibiting similar genomic sequences (Carstens et al. 2015, Doan 
et al. 2015, Smith et al. 2015) have recently been published, they have not been characterized in 
the laboratory; their growth parameters and mechanisms of infection are unknown. Within the 
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Putonti lab both Greedy and Lust have been tested against several E. coli laboratory strains and 
clinical E. coli isolates from the bladder, including strains from patients suffering from UTIs, 
cystitis, and pyelonephritis as well as asymptomatic “healthy” individuals. While both Lust and 
Greedy can lyse some E. coli strains from UTI patients, they were unable to lyse all UTI-
associated E. coli strains tested. This is not surprising as the differences in genotype and 
phenotype between the E. coli strains themselves are unknown and the same symptoms may 
have different etiologies. Against this subset of bacteria tested, however, it is worth noting that 
Greedy exhibited a broader host range than Lust as it was successful in infecting and lysing more 
E. coli strains (in particular clinical strains) than Lust (Putonti et al., in preparation). The 
observed difference between Greedy and Lust’s ability to reduce the E. coli biofilm is an 
interesting area for further investigation. 
 In contrast to the coliphages, the Pseudomonas-infecting phages phiKZ and DMS3 have 
been extensively characterized in the laboratory. In a study using the same strain of P. 
aeruginosa used here, they found that phage KTN4 (a phiKZ-like-virus) disturbed biofilms and 
reduced the production of pyocyanin and sideophores (Danis-Wlodarczyk et al. 2004). 
Pyocyanin is a P. aeruginosa produced toxin that gives it its characteristic green color and plays 
a role in biofilm formation (Lao et al. 2004). PhiKZ has also been used in studies that 
aerosolized phage to test the feasibility of using inhalers to treat P. aeruginosa lung infections 
(Golshahi et al. 2011, Matinkhoo et al. 2011). PhiKZ was found to have a dose dependent effect 
on P. aeruginosa infections in mice lungs (Henry et al. 2013). Another study used phiKZ, along 
with other Pseudomonas phages, to test the resilience of clinical isolates from chronic P. 
aeruginosa infections; they found that these isolates had an increased susceptibility to phage 
infection (Friman et al. 2013). DMS3 has been studied with particular relevance to its effect on 
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biofilms. It has been shown to reduce swarming motility in P. aeruginosa PA14 via the CRISPR-
Cas system (Zegans et al. 2009, Chung et al. 2012). Furthermore, DMS3 lysogeny blocks 
biofilm formation in P. aeruginosa PA14 with a 50% reduction of attachment in the first 30 mins 
(Zegans et al. 2009). Given this prior work, it is thus not surprising that DMS3 was effective in 
disrupting the viability of the P. aeruginosa biofilm (Figure 8D). 
 Phage treatments for biofilms of non-host species included the treatment of P. mirabilis 
biofilms with all five phages, coliphage treatment of P. aeruginosa biofilms, and Pseudomonas 
phage treatment of E. coli biofilms. Figure 9 shows the absorbance measurements of these 
treatments while Figure 10 shows the colony counts for these treatments. Looking first at the 
absorbance results, no statistically significant effect in the P. mirabilis biofilms was observed 
(Figure 9A). While visually it appears that the Habibi treatment did lead to a decrease in P. 
mirabilis biofilms (per absorbance measurements), this was not statistically significant 
(P=0.281). In contrast, treatment of E. coli biofilms by both Pseudomonas-infecting phages had 
an effect (Figure 9B). E. coli absorbance data was normalized (box-cox transformation, 
lambda=-0.94) and an ANOVA was performed (F2,6=45.63 P=0.000235). The effect of phiKZ 
(relative to the untreated control biofilms) was statistically significant (P<0.001) as was the 
effect of DMS3 (P<0.001). No statistically significant effect was identified for coliphage 
treatments of P. aeruginosa biofilms (Figure 9C). 
 To ascertain if the treatments had an effect on the viable bacterial community of the 
biofilm, colony count data was considered (Figure 10). Paralleling that observed for the 
absorbance data (Figure 9), no significant effect was observed for the P. mirabilis (Figure 10A) 
and P. aeruginosa (Figure 10C) biofilms. However, the Pseudomonas phages phiKZ and DMS3 
treatment of the E. coli biofilms had an effect on the biofilm community; E. coli colony count 
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data was normalized (box-cox transformation, lambda= -0.69) and an ANOVA was performed 
(F2,6=20.64 P=0.00204). PhiKZ (P=0.00546) and Greedy (0.00245) were found to be 
significantly different from the control treatment. 
 
Figure 9. Effects on the biofilms, as measured by absorbance, for phage treatments of non-host 
phage species. (A) Treatments for all five phages on P. mirabilis biofilms. (B) Treatments for 
phiKZ and DMS3 phages on E. coli biofilms. (C) Treatments of coliphages Lust and Greedy on 
P. aeruginosa biofilms. An asterisk denotes a statistically significant difference by Tukey’s 
multiple comparison test where *** indicates a P-value < 0.001. 
 
 
Figure 10. Effects on the biofilms, as measured by colony counts, for phage treatments of non-
host phage species. (A) Treatments for all five phages on P. mirabilis biofilms. (B) Treatments 
for phiKZ and DMS3 phages on E. coli biofilms. (C) Treatments of coliphages Lust and Greedy 
on P. aeruginosa biofilms. An asterisk denotes a statistically significant difference by Tukey’s 
multiple comparison test where ** indicates a P-value < 0.01. 
 
 It is interesting that P. aeruginosa phages had a significant effect on E. coli biofilms 
despite their inability to lyse E. coli. Lysis is not the only way that a phage can inhibit bacterial 
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growth. For example, as mentioned previously, when DMS3 switches to lysogeny it inhibits P. 
aeruginosa biofilm formation (Zegans et al. 2009). Adsorption induced lysis as a result of high 
concentrations of phage is another possibility (Abdeon 2011, Turner and Chao 1998). 
Additionally, phages may produce toxins or enzymes that inhibit bacterial growth, or perhaps the 
phages are attaching to the cell wall but are unable to degrade and enter the cell. There is still 
much to learn about bacteriophages and the ways they interact with bacteria. 
Effects of Phage Treatment on Heterogenous Biofilms 
In addition to the phage treatments applied to homogenous biofilms of E. coli, P. aeruginosa, 
and P. mirabilis, complex communities of biofilms were created. Biofilms consisting of each 
pair as well as all three of these CAUTIs-associated bacteria were established in the same 
manner as the homogeneous biofilms (see Methods). Thus, four heterogeneous biofilms were 
considered in this study: E. coli and P. aeruginosa (EP), E. coli and P. mirabilis (EM), P. 
aeruginosa and P. mirabilis (PM), and all three bacteria (EPM). Again, each treatment was 
conducted in triplicate in addition to a control (no treatment). 
 While absorbance measures revealed that Lust and Greedy phage treatments had a 
statistically significant effect on homogeneous E. coli biofilms (Figure 8A), the same cannot be 
said for the heterogeneous biofilms. As shown in Figure 11, no statistically significant effect was 
detected by means of absorbance for any of the heterogenous biofilms treated with any of the 
phage. Total colony count data, however, show a different trend; several of the treatments of the 
PM (Figure 12C) and EPM (Figure 12D) biofilms reveal significant effects. The total colony 
count represents the number of viable bacteria, regardless of species, in the heterogenous 
biofilm. The PM total colony count data was normalized (log-transformation) and an ANOVA 
was performed (F5,12=3.466 P=0.0361). A significant effect to the biofilm was only found when 
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considering the untreated (control) and Lust treatments (P=0.0294) (Figure 12C). The EPM total 
colony count data was also log-transformed and an ANOVA was performed (F5,12=5.096 
P=0.00977). As Figure 12D shows, a significant difference was found between the untreated 
control and four of the treatment regimens: Greedy (P=0.03056), Lust (P=0.00998), phiKZ 
(P=0.02728), and Habibi (P=0.01750). 
 
Figure 11. Effects of phage treatments, quantified by absorbance, on heterogenous biofilms of: 
(A) E. coli and P. aeruginosa, (B) E. coli and P. mirabilis, (C) P. aeruginosa and P. mirabilis, 
and (D) E. coli, P. aeruginosa, and P. mirabilis. 
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Figure 12. Effects of phage treatments, quantified by total colony count, on heterogenous 
biofilms of: (A) E. coli and P. aeruginosa, (B) E. coli and P. mirabilis, (C) P. aeruginosa and P. 
mirabilis, and (D) E. coli, P. aeruginosa, and P. mirabilis. An asterisk denotes a statistically 
significant difference by Tukey’s multiple comparison test where * indicates a P-value < 0.05 
and ** indicates a P-value < 0.01. 
 
 While Figure 12 captures the overall viability of the biofilm community, we were 
interested in investigating specifically how each of the phage treatments impacted the individual 
constituents of the complex community. Thus, for each plate, individual colonies were identified 
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by species based upon their morphological features. Figures 13 and 14 present a breakdown of 
the colony counts by species for the two-species biofilms and three-species biofilms, 
respectively.  
 Where we saw four of the five phage treatments were significantly different from the 
control in EPM biofilms in regards to total colony counts (Figure 12), we only see a significant 
effect in P. aeruginosa individual colony counts (Figure 14). P. aeruginosa colony counts were 
normalized (log-transformation) and ANOVA was performed (F5,12=4.403 P=0.0165). PhiKZ 
was found to have a significant effect on EPM biofilms (P=0.0397). Furthermore, for the two-
species biofilms we see significant effects with respect to P. aeruginosa colony counts in PM 
biofilms (Figure 13F). After log-transformation, an ANOVA was performed (F5,12=5.311 
P=0.00838), and effects were found for both phiKZ (P=0.0124) and DMS3 (P=0.0397). We also 
identified a significant difference between treatments for E. coli colony counts in the EM 
biofilms when a Kruskal-Wallis was performed (χ2=15.739, df=5, P=0.007631). P. mirabilis 
colony counts (log-transformed) also showed a significant ANOVA in EM biofilms (F5,12=3.548 
P=0.0336); there was a significant difference between Greedy and Lust treatments (P=0.0403). 
For E. coli colony counts treated with Greedy, no colonies were observed at the dilutions plated. 
To perform a box-cox transformation (lambda=0.23) 1.0e+04 was used in place of zero, this 
number was chosen because it is the dilution E. coli colonies plated at when homogenous E. coli 
biofilms were treated with Greedy. Then an ANOVA was performed (F5,12=4.146 P=0.0203); 
Greedy (P=0.0213) and Habibi (P=0.0250) were significantly different from control treatments.  
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Figure 13. The effects of phage treatments, quantified by species colony counts, on 
heterogenous biofilms. (A) P. aeruginosa colony counts in E. coli and P. aeruginosa biofilms, 
(B) P. mirabilis colony counts in E. coli and P. mirabilis biofilms, (C) P. mirabilis colony counts 
in P. aeruginosa and P. mirabilis biofilms, (D) E. coli colony counts in E. coli and P. aeruginosa 
biofilms, (E) E. coli colony counts in E. coli and P. mirabilis biofilms, and (F) P. aeruginosa 
colony counts in P. aeruginosa and P. mirabilis biofilms. An asterisk denotes a statistically 
significant difference by Tukey’s multiple comparison test where * indicates p<0.05. 
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Figure 14. The effect of phage treatments, quantified by species colony counts, on heterogenous 
E. coli, P. aeruginosa, and P. mirabilis biofilms. (A) E. coli colony counts, (B) P. aeruginosa 
colony counts, and (C) P. mirabilis colony counts.  
 
Biofilm Response to Treatment with Broad Host Range Phage Habibi 
Given Habibi’s ability to infect both E. coli and P. aeruginosa, we originally hypothesized that it 
would be an effective phage treatment for both homogenous biofilms of E. coli and P. 
aeruginosa as well as a heterogeneous biofilm containing the two bacteria species. While 
presented in prior figures, the direct comparisons for no treatment and Habibi treatments are 
shown here. While absorbance data indicated no significant effects (Figure 15), a statistically 
significant effect was detected using colony counts data for the P. aeruginosa biofilms (Figure 
16C) as well as for the E. coli population of the EP biofilms (Figure 16B). 
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Figure 15. Effects of Habibi phage treatments on (A) E. coli, (B) P. aeruginosa, and (C) E. coli 
and P. aeruginosa biofilms, assessed via absorbance. 
 
 When considering the viable bacteria within the heterogeneous EP biofilm, we 
anticipated that Habibi treatment would have a greater effect on Pseudomonas as we have 
previously observed a higher plating efficiency of Habibi on P. aeruginosa relative to E. coli C. 
The homogenous P. aeruginosa biofilms supported this conjecture (Figure 16C). P. aeruginosa 
colony count data for P. aeruginosa biofilms was normalized (box-cox transformation, lambda= 
-0.38) and an independent sample t-test was performed (t=4.4422, df=2.4384, p=0.03235). 
Despite this observation for the homogenous biofilm, the P. aeruginosa colony count from the 
EP biofilm Habibi treatments did not show a decrease in the number of viable cells. From a 
purely visual inspection of the log-transformed data in Figure 16D, Habibi had a varied effect on 
the P. aeruginosa cells; one of the replicates had 10x more P. aeruginosa colonies than the other 
two replicates. A statistically significant effect was observed for the E. coli colonies within these 
same treatments of the heterogenous EP biofilms. E. coli colony counts for EP biofilms were 
normalized (log-transformation) and an independent samples t-test was performed (t=4.508, 
df=3.8486, P=0.01175). E. coli densities between the three replicates were consistent. 
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Figure 16. Effects of Habibi phage treatments, quantified by colony counts, on (A) E. coli in 
homogeneous E. coli biofilms, (B) the E. coli population in EP biofilms, (C) P. aeruginosa in 
homogeneous P. aeruginosa biofilms, and (D) the P. aeruginosa population in EP biofilms. An 
asterisk denotes a statistically significant difference by Tukey’s multiple comparison test where * 
indicates a P-value < 0.05. 
 
Biofilm Response to Treatment with Phage Cocktails 
Due to the fact that the broad host range phage of Habibi was not effective in reducing both the 
P. aeruginosa and E. coli populations of the EP biofilm, we decided to try and target the two 
bacteria by means of a phage cocktail. From the individual phage treatments of both 
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homogeneous and heterogeneous biofilms, the coliphage Greedy and the Pseudomonas phage 
phiKZ were selected for the phage cocktail. As with Habibi, we assessed the differences between 
Greedy, phiKZ, and Greedy+phiKZ (henceforth denoted as “G+phi”) treatments by both the 
recorded absorbance (Figure 17) and single species colony count data (Figure 18). 
 The E. coli biofilm absorbance data was normalized using the box-cox transformation 
(lambda=-0.94). As shown in Figure 17A, we see that every phage treatment was significantly 
different from the untreated control (ANOVA, F3,8=18.2 P=0.000622). Tukey’s multiple 
comparison test was performed finding statistical significance between: untreated and G+Phi 
treatment (P= 0.00575), untreated and Greedy (P= <0.001), and untreated and phiZK 
(P=0.00434). The absorbance data collected for the P. aeruginosa biofilms was log transformed 
and an ANOVA was performed. In contrast to the results observed for the E. coli biofilms, none 
of the phage treatments had a significant effect on the P. aeruginosa biofilm per the absorbance 
measure (Figure 17B). In the heterogenous EP biofilms (Figure 17C), only the G+Phi treatment 
was statistically significant in relation to the untreated biofilms (ANOVA, F3,8=17.39 
P=0.00726). Tukey’s multiple comparison test between untreated and G+Phi treatment resulted 
in P= 0.00285. 
 Statistically significant effects due to phage treatment of the E. coli biofilms were also 
observed when considering colony counts. In Figures 18A and 18B we see a significant effect in 
the E. coli populations after treatment of both the E. coli and EP biofilms. Colony counts from 
the E. coli biofilms were log-transformed and an ANOVA was performed (F3,8=33.74 P=6.87e-
05). Tukey’s multiple comparison test was performed finding statistical significance between: no 
treatment and G+Phi treatment (P= <0.001) and no treatment and Greedy (P= <0.001). Phage 
treatment of the E.coli population in EP biofilms was also significant (box-cox transformed, 
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lambda=0.07; ANOVA, F3,8=103.4 P= 9.74e-07). Tukey’s multiple comparison test was next 
performed identifying statistical significance between the control (no treatment) and the G+Phi 
treatment (P<0.001) and between the control (no treatment) and the Greedy treatment (P<0.001). 
 
Figure 17. Effect of phage treatment of Greedy, phiKZ, and Greedy+phiKZ cocktail on (A) E. 
coli, (B) P. aeruginosa, and (C) EP biofilms based upon absorbance (660 nm). An asterisk 
denotes a statistically significant difference by Tukey’s multiple comparison test where *** 
indicates a P-value < 0.001 and ** indicates a P-value < 0.01. 
 
 While the absorbance assays indicated no significant effect in the concentration of P. 
aeruginosa bacterial cells (or cell matter) within the homogenous biofilm, colony counts tell a 
different story. In Figures 18C and 18D, a significant effect is observed for phage treatment of 
both the P. aeruginosa and EP biofilms. P. aeruginosa biofilms’ (log transformed) ANOVA was 
significant (F3,8=7.405 P= 0.0107); Tukey’s multiple comparison test between no treatment and 
phiKZ treatment is statistically significant (P= 0.0166). Similar statistics were performed for the 
P. aeruginosa colony count data from the EP biofilms (log-transformed ANOVA, F3,8=18.22 P= 
0.000619; Tukey’s multiple comparison test between no treatment and G+Phi treatment (P= 
0.00908). 
44 
 
 
Figure 18. Effects of phage treatments of Greedy, phiKZ, and Greedy+phiKZ (G+Phi) cocktail 
on (A) E. coli in homogeneous E. coli biofilms, (B) the E. coli population in EP biofilms, (C) P. 
aeruginosa in homogeneous P. aeruginosa biofilms, and (D) the P. aeruginosa population in EP 
biofilms. An asterisk denotes a statistically significant difference by Tukey’s multiple 
comparison test where * indicates a P-value < 0.05, ** a P-value< 0.01, and *** a P-value< 
0.001. 
 
 From the results of the cocktail treatments, in particular the colony counts presented in 
Figure 18, three observations can be made. First, Greedy was highly efficient in reducing the 
number of viable cells within the homogeneous E. coli biofilm. This efficiency in killing E. coli 
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cells was also apparent when it was used to treat the EP biofilm (Figure 18B). While it had no 
substantial effect on the P. aeruginosa biofilm (Figure 18C) it produced a dramatic effect on the 
P. aeruginosa population within the EP biofilm. While Greedy is highly unlikely to have 
“promoted” P. aeruginosa growth, this is likely a residual effect of its efficacy in lysing E. coli 
cells within the biofilm. Thus, we speculate that the decline in E. coli within the treated EP 
biofilms increased the resources available for P. aeruginosa growth. Based on P. aeruginosa’s 
ability to persist and even proliferate in the absence of E. coli within these treated biofilms, we 
hypothesize that the two bacteria species are not as cooperative as has been observed within 
other multispecies biofilms (Nozhevnikova et al. 2015) and may even be antagonistic, fighting 
for resources. Secondly, phiKZ was only found to produce a significant effect on the 
homogeneous P. aeruginosa population. The cocktail, however, was not found to be significant 
in the P. aeruginosa biofilm, perhaps because of the reduced titer of phiKZ. Lastly, the phage 
cocktail was effective on both bacteria species within the heterogenous EP biofilm. 
Planktonic Fraction 
The planktonic fraction, or the free-living independent bacteria outside of the biofilm, have 
substantially different metabolic characteristics (Davey and O’Toole 2000). They are, 
nevertheless, a vital part of the ecosystem representative of bacterium which can be recruited and 
integrated during biofilm development or dispersed members of a biofilm (Figure 1). Thus, in 
addition to examination of the biofilm bacterial communities, the planktonic fraction was also 
evaluated post-treatment. The same metrics were used to evaluate the planktonic fraction as were 
used for evaluation of the biofilms. The absorbance data and colony counts from the planktonic 
fraction of the homogeneous biofilm treatments and the heterogeneous biofilm treatments are 
shown in Figures 19 and 20, respectively. 
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 For the E. coli biofilm’s planktonic fraction, we detected a significant difference in 
absorbance between the treatments (Figure 19A); a Kruskal-Wallis test was found to be 
significant (χ2 = 14.099, df = 5, P= 0.01499). Similarly, the five treatments had different effects 
on the bacterial community within the planktonic fraction of the P. aeruginosa biofilms (Figure 
19B). The Kruskal-Wallace χ2 statistic = 14.17, df = 5, p-value = 0.01457. As expected, no 
significant effect was observed for the P. mirabilis community. 
 In addition to measuring the absorbance, aliquots from the planktonic fraction were 
plated and colonies counted (see Methods). For the E. coli biofilm treatments, an ANOVA was 
performed (F5,12=18.4 p=2.96e-05). As Figure 19D shows, only the Greedy treatment was found 
to have a statistically significant relative to the untreated control (P=0.00603). To assess the 
putative effects on the P. aeruginosa population within the planktonic fraction, the colony count 
data was normalized (log-transformation) and an ANOVA was performed (F5,12= 20.41 p=3.15e-
05). PhiKZ (P=0.01726), DMS3 (P<0.001) and Habibi (P=0.00386) were found to have a 
significant effect relative to the untreated (control) biofilm planktonic fraction (Figure 19E). 
Again as expected, no significant effect was observed for the planktonic fraction’s P. mirabilis 
community. 
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Figure 19. Effects of phage treatments on the planktonic fraction of homogenous E. coli, P. 
aeruginosa, and P. mirabilis biofilms measured by absorbance (panels A through C) and colony 
counts (panels B through D). An asterisk denotes a statistically significant difference by Tukey’s 
multiple comparison test where * indicates a P-value < 0.05, ** denotes a P-value < 0.01, and 
*** indicates a P-value < 0.001. 
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Figure 20. Effects of phage treatments on the planktonic fraction of heterogeneous biofilms 
measured by absorbance (panels A through D) and colony counts (panels F through I). 
 
 Evaluation of the effects of phage treatment within the planktonic fraction was next 
evaluated for the heterogenous biofilms, again using absorbance (Figure 20, panels A through D) 
and total colony counts (Figure 20, panels F through I). From these total colony counts, the only 
statistically significant result was from an ANOVA of the EPM treatments (F5,12=3.629 
p=0.0313). given this observed difference, Tukey’s multiple comparison test was performed. 
While no statistically significant difference between the control and individual treatments was 
found, the Lust treatment was significantly different from Greedy treatment (P=0.018); this 
difference between Lust and Greedy was the reason the ANOVA produced a significant result. 
 To ascertain if the changes in total colony counts were due to an individual species, we 
next investigated these colony counts by species (Table 4). The most intriguing result found was 
the increase in P. mirabilis in the EM and PM biofilm planktonic fraction in response to 
treatment by Greedy. While one could hypothesize that this increase in the EM was due to the 
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effectiveness of Greedy in lysing E. coli cells, and thus reducing resource constraints for P. 
mirabilis, it is confounding to see a similar – and more profound – effect in the PM biofilm’s 
planktonic fraction. This warrants further investigation of P. mirabilis and P. aeruginosa 
interactions within liquid culture. 
Biofilm Bacteria 
Treatment 
None Lust Greedy PhiKZ DMS3 Habibi 
EP E. coli 6.73E+07 7.07E+07 N/A 6.40E+07 8.03E+07 2.27E+07 
P. aeruginosa 3.17E+07 2.23E+07 1.42E+08 N/A N/A 1.33E+06 
EM E. coli 2.00E+06 N/A N/A 2.50E+07 0.00E+00 0.00E+00 
P. mirabilis 1.72E+08 1.15E+08 6.08E+08 1.06E+08 1.27E+08 1.53E+08 
PM P. aeruginosa 9.00E+06 6.67E+06 9.00E+06 N/A N/A 6.67E+05 
P. mirabilis 2.93E+08 1.50E+08 1.51E+09 2.25E+08 2.39E+08 1.59E+08 
EPM E. coli 1.10E+07 N/A 6.67E+05 7.00E+06 2.60E+07 1.67E+06 
P. aeruginosa 7.00E+06 4.00E+06 2.33E+06 N/A 3.33E+05 1.33E+06 
P. mirabilis 1.19E+08 9.87E+07 1.82E+08 1.20E+08 1.21E+08 1.48E+08 
Table 4. Colony counts within the planktonic fraction for heterogeneous biofilm treatments by 
species. N/A means that no colonies grew at the dilutions plated. 
 
Host Resistance to Phage Infection 
Because no single phage or the phage cocktail completely destroyed the biofilms, although 
Greedy was close to successful for the E. coli biofilm treatments (Figure 8A and B), we next 
determined if the resilience of the biofilm was the result of bacterial resistance to the phage. 
Randomly selected bacterial colonies were thus selected and challenged by the phage used in the 
treatment (see Methods Figure 7). As expected, P. mirabilis remained resistant to all five phages, 
regardless if it was a homogeneous or heterogenous biofilm. Figure 21 provides a graphical 
representation of the resistance observed for E. coli colonies from the five treatment regimens of 
E. coli biofilms (Figure 21A) and the planktonic fraction (Figure 21C). Figure 21 panel B and D 
show the results for the P. aeruginosa colonies in the biofilm and planktonic fraction, 
respectively. 
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Figure 21. Bacterial resistance for bacterial isolates from within homogeneous biofilms. NT 
signifies isolates collected from the untreated (control) biofilms, and T represents those collected 
for the phage treatment samples. Panels A and B present the percentage of colonies resistant, 
partially resistant, or phage-sensitive from the E. coli and P. aeruginosa biofilms, respectively. 
Panels C and D include the percentages for colonies from the planktonic fraction of E. coli and 
P. aeruginosa biofilms, respectively. 
 
 Colonies from both the untreated (NT) and treated (T) samples are included in the graph. 
The NT bar charts represent the likelihood of resistance occurring a priori. It is important to note 
that phage sensitivity is not an absolute in, for example, E. coli. Colonies resistant to Greedy 
were observed both in the biofilm as well as the planktonic fraction (21A and C). Also of note is 
the occurrence of E. coli colonies which were sensitive to either phiKZ or DMS3 which is not 
believed to be infective of bacteria outside of the Pseudomonas genus. While these innate 
resistances and sensitivities may have arisen as a result of the selection experiment deriving the 
strains used for our experiment, the fact that they are seen in such small numbers suggests this is 
51 
 
 
not the case. Similar unexpected results were observed for the NT colonies tested from the P. 
aeruginosa experiments. In fact, the majority of the biofilm colonies were resistant or partially 
resistant to phiKZ and DMS3 and all of the biofilm colonies were resistant or partially resistant 
to Habibi. This may be a contributing factor to the minimal effect observed for the Habibi 
treatments (Figures 15 and 16). Furthermore, the ability for a phage to infect and successfully 
lyse a bacteria cell is traditionally assayed either via liquid culture or on a plate, as we have done 
here. The ability for a phage to lyse within the unique spatial organization of a biofilm is 
unknown. 
 For the four complex biofilms, resistance was tested for colonies of each (in the case of 
EP, EM, and PM) or all three (EPM) bacterial species. In complex biofilms with E. coli present 
treatment with Greedy and Lust resulted in few if any E. coli colonies growing at the dilutions 
plated. As such, we were unable to test for host resistance. Similarly, in multispecies biofilms 
with P. aeruginosa present treatment with PhiKZ, DMS3 and Habibi resulted in few if any P. 
aeruginosa colonies growing at the dilutions plated for the planktonic fraction. Thus, only P. 
aeruginosa from the biofilm was able to be tested for host resistance. Partial susceptibility to 
phage infection was more common in P. aeruginosa than E. coli. Table 5 summarizes the results 
of these resistance assays for the heterogenous biofilms for colonies isolated from the biofilms 
themselves, while Table 6 summarizes the results from the planktonic fraction. The results in 
Table 6 show an intriguing trend in which the P. aeruginosa colonies from the phage treatments 
were more sensitive than the untreated cultures. This contradicts our assumptions that resistance 
arises in response to phage predation and thus warrants further investigation. The results of the 
resistance assays for the G-phi treatments are shown in Figure 22. 
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Category 
Phage 
Lust Greedy phiKZ DMS3 Habibi 
E
. 
co
li
 
N
T
 Resistant 0 0 24 26 0 
Partial 0 0 3 0 7 
Sensitive 27 27 0 1 20 
T
 
Resistant 0 0 25 27 10 
Partial 0 0 1 0 8 
Sensitive 9 2 0 0 3 
N/A 18 25 1 0 6 
P
. 
a
er
u
g
in
o
sa
 
N
T
 Resistant 27 27 0 0 0 
Partial 0 0 24 26 25 
Sensitive 0 0 3 1 2 
T
 
Resistant 27 27 3 1 0 
Partial 0 0 19 15 22 
Sensitive 0 0 1 11 5 
N/A 0 0 4 0 0 
Table 5. Bacterial resistance for isolates from within heterogeneous biofilms. 
 
 
Category 
Phage 
Lust Greedy phiKZ DMS3 Habibi 
E
. 
co
li
 
N
T
 Resistant 0 0 26 25 0 
Partial 0 0 1 2 11 
Sensitive 27 27 0 0 16 
T
 
Resistant 0 0 22 27 20 
Partial 0 0 5 0 2 
Sensitive 9 1 0 0 0 
N/A 18 26 0 0 5 
P
. 
a
er
u
g
in
o
sa
 
N
T
 Resistant 27 27 3 3 3 
Partial 0 0 20 20 22 
Sensitive 0 0 4 4 2 
T
 
Resistant 27 27 0 0 0 
Partial 0 0 0 1 11 
Sensitive 0 0 0 0 1 
N/A 0 0 27 26 14 
Table 6. Bacterial resistance for isolates from within planktonic fraction of heterogeneous 
biofilms. 
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Figure 22. Bacterial resistance for isolates treated with phage cocktail within the (A) biofilm and 
(B) planktonic fraction. Areas denoted by the hashed bar indicate samples for which the 
effectiveness of the phage treatment resulted in no retrievable colonies of the particular bacteria. 
 
Phenotypic Changes in Bacterial Species 
 In addition to determining the relative number of viable colonies for each species present 
in a biofilm, plating also allowed us to observe multiple morphological changes in colony 
phenotype. In six of the samples containing P. aeruginosa, a red colony morphology was 
observed (Figure 23). These samples included isolates from both the biofilm and planktonic 
fraction of the same replicate of the untreated Pseudomonas control. Two of the replicates from 
the Pseudomonas biofilm treated with phiKZ also contained a “Red Pseudomonas.” Other 
samples include one replicate of the untreated PM planktonic fraction, one replicate of 
Pseudomonas treated with Habibi, and two replicates of Pseudomonas treated with G+phi. These 
colonies appeared as normal, however once streaked on an LB plate, a red pigment was diffused 
through the agar. Pseudomonad species are known to diffuse colored pigments throughout their 
media. The P. aeruginosa 1C strain, used routinely in our lab, typically produces pyocyanin 
which is responsible for its characteristic green color and pyomelanin (brown) when the culture 
is old (Ogunnariwo and Hamilton-Miller 1974). This was the first time we observed the red-
brown pigment pyorubin in our laboratory strain.  
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Figure 23. P. aeruginosa red colony phenotype. 
 
 P. aeruginosa biofilms treated with DMS3, phiKZ, or Habibi resulted in numerous 
colonies presenting a morphology quite different from those observed in untreated biofilms. 
Altered phenotypes consisted of P. aeruginosa colonies which maintained their color but were 
usually smaller in size and appeared as though pieces of their colonies were missing. These 
colonies had jagged edges rather than their normal circular shape. Restreaking these colonies 
resulted in their return to normal colony morphology; thus, the change in morphology was not 
likely due to a genetic source as it was not inheritable. These phenotypes had higher frequencies 
in the planktonic fraction than the biofilm portion of the samples. This is consistent with 
previous findings that show P. aeruginosa phages are effective at reducing additional biofilm 
formation by preventing the aggregation of dispersed members of the biofilm in the planktonic 
fraction (Darch et al. 2017). 
 Novel colony morphologies were also observed in E. coli biofilms treated with Lust and 
Greedy. E. coli colonies were smaller and jagged-edged in contrast to smooth-edged. Despite the 
fact that these two phages were isolated in our lab (Malki et al. 2015) and have been plated with 
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E. coli C numerous times prior, this was the first time this E. coli C morphology has been 
observed. As a precaution, the E. coli C biofilm treatment with Greedy was repeated, again in 
triplicate, and produced similar E. coli C cell morphologies. Colonies from these plates were 
selected and restreaked producing a second generation of aberrant colonies. Furthermore, in 
contrast with the E. coli C lab strain in our collection (and the ancestor of the inoculant of the 
biofilms), the restreaked E. coli grew slower. It is important to note that not all colonies on a 
plate showed these altered morphologies, and similar to phenotypic responses observed in P. 
aeruginosa, the altered colonies were more frequently observed in the planktonic fraction rather 
than in the biofilm community. This observation is consistent with the protective nature of 
biofilms. 
 An additional change to colony morphology was observed in biofilms containing both E. 
coli and P. aeruginosa treated with DMS3. Here a few colonies from the biofilm portion of the 
samples appeared to have swarming abilities. While frequently observed for P. aeruginosa and 
P. mirabilis colonies from all biofilms, E. coli swarming colonies were only observed in EPD 
biofilms. Perhaps this morphology was a result of horizontal gene transfer which occurs in 
higher rates in biofilms (see review Madsen et al. 2012).  
Phage Populations within Treatments 
While spotting phage to test host range and isolate individual plaques for identification, the last 
dilution at which plaquing occurred was recorded, though specific titers were not. From this we 
noticed a few interesting trends. As expected the concentration of phage was higher in the 
planktonic fraction than the biofilm fraction of samples for every phage. Additionally, all phages 
except Habibi had their lowest concentrations in EPM biofilms, for Habibi it was E. coli 
biofilms. Another interesting observation about Habibi was that it had a higher concentration in 
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EM biofilms than E. coli biofilms despite no observed plaques on P. mirabilis lawns. Something 
similar occurred with phage DMS3 which had equal concentration of phage in P. aeruginosa and 
EP biofilms despite a lack of plaques on E. coli lawns. This is probably because when treated 
with DMS3 EP biofilms did better than P. aeruginosa biofilms. Furthermore, this is intriguing 
when you consider the fact that while DMS3 and Habibi had no plaques on E. coli or P. mirabilis 
lawns; after treatment of EM, PM, and EPM biofilms, both phages resulted in visibly less turbid 
lawns when spotted on E. coli and P. mirabilis. This was not observed in E. coli or P. mirabilis 
biofilms treated with the phages individually. Lust had its highest concentrations in EP and EM 
biofilms. Greedy did the best in E. coli biofilms. PhiKZ and DMS3 were most successful in P. 
aeruginosa biofilms. Habibi saw its highest concentrations in EP biofilms, which was expected 
considering its ability to infect both members of the biofilm.  
Pseudomonas aeruginosa Prophage 
Despite previously unsuccessful attempts from members of our lab trying to manipulate P. 
aeruginosa to release its prophage, throughout this experiment we observed the prophage 
multiple times. A prophage is a bacteriophage genome inserted into the bacterial chromosome or 
plasmid that is only released upon activation by things such as host stress (Figure 24). It was 
released in untreated P. aeruginosa biofilms and also in untreated biofilms composed of both P. 
aeruginosa and E. coli. Interestingly, it was not released in untreated biofilms containing P. 
mirabilis (PM or EPM biofilms). Additionally, the prophage was not released in P. aeruginosa 
biofilms treated with either Lust or Greedy. However, in EPM biofilms treated with Lust, one 
replicate showed the appearance of the prophage. In EPM biofilms treated with Greedy, the 
prophage appeared in all three replicates.  Plaque morphology was observed as pin point plaques 
with crisp edges and a very clear center. Upon spotting the prophage on both E. coli and P. 
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mirabilis lawns, no lysis was observed. In a few instances, spotting the prophage on P. 
aeruginosa resulted in plaquing that was not confined to the spots but rather was observed 
throughout the plate.  
 
Figure 24. Bacteriophage life cycle. 
 
 Prophage concentrations ranged from 102-108 with planktonic concentrations about 10-
fold higher than their biofilm counterparts. In all cases except P. aeruginosa untreated biofilms, 
the concentration of prophage released was higher in replicates with higher absorbance values 
and thus thicker biofilms. Combined, these observations suggest that there is a relationship 
between prophage release and increased biofilm production in our strain of P. aeruginosa. This 
hypothesis is supported by other studies observing a similar correlation. For instance, 
Streptococcus pneumoniae biofilm production is aided by prophage mediated lysis which 
releases DNA into the environment which aides in biofilm formation as extracellular DNA is an 
important component of the matrix (Carrolo et al. 2010). Enhanced biofilm formation due to 
phage mediated release of DNA was also observed in Shewanella oneidensis (Gödeke, et al. 
2011), and E. faecalis (Rossman et al. 2015).  
 58 
CHAPTER FOUR 
 
CONCLUSION 
 
Our examination of the literature found phage to be more effective at biofilm inhibition than 
eradication, as such we did not initially expect any of our phages to substantially reduce biofilm 
density. In this aspect the effects of Greedy treatments exceeded our expectations. We saw that 
Greedy produced statistically significant reductions in homogeneous biofilms, when compared to 
the control, quantified by both absorbance and colony counts. We also found Greedy’s effect 
spread into the E. coli colony counts in the planktonic fraction. Furthermore, Greedy had a 
significant effect in EPM biofilms, with regards to the total colony count data, and in EP biofilms 
(for E. coli colony counts). When combined with phiKZ, the cocktail treatment of EP biofilms 
resulted in a significant effect, per the absorbance data. This is particularly intriguing as 
absorbance data represents both the viable and non-viable portions of the biofilm, thus giving a 
more accurate representation of biofilm density. Greedy treatments also produced altered colony 
morphologies; bacterial colonies were both smaller and had a slower growth rate relative to their 
ancestor. As on-going research in our lab characterizing Greedy has found, it is able to infect and 
lyse several clinical E. coli strains isolated from patients presenting with UTIs. For these reasons, 
we believe that Greedy is a strong candidate for future research in biofilm reduction, and more so 
in phage treated catheter studies for biofilm prevention. Follow up studies, investigating the 
effectiveness of Greedy in preventing biofilm formation as well as the efficacy of Greedy 
treatments over time, would provide greater insight into its potential for phage therapy. 
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 This study was the first, to our knowledge, to examine three species biofilms composed 
of CAUTI-associated bacteria. Despite catheter biofilms, and biofilms in general, being 
composed of multiple species of bacteria, much of the current research focuses on homogenous 
biofilms. Prior studies have found catheter biofilms containing up to five different bacterial taxa 
(Saint and Chenoweth 2003). As we have shown here, an effect on a single species biofilm is not 
necessarily reflected in more complex, heterogeneous biofilms. For example, while Lust had a 
significant effect on E. coli biofilm absorbance, it loses that effect in EP, EM and EPM biofilm 
absorbance. We did not observe any significant effects of any phage treatment on heterogenous 
biofilms quantified by absorbance. Furthermore, we saw no significant effects, based on total 
colony counts, in EP biofilms despite all five of our phages infecting both species within it. We 
urge future studies to consider the more naturally occurring complex, multispecies biofilms. 
Among the many interesting results of this study, perhaps the most alarming observation 
was the effect of phage treatment on non-host bacteria. While P. mirabilis was not significantly 
affected by any of the phage treatments, we did see an inflation of P. mirabilis colonies counts in 
the planktonic fraction of EM and PM biofilms in response to treatment with Greedy. 
Furthermore, P. aeruginosa phage treatments with phiKZ and DMS3 also had a significant effect 
on E. coli biofilms; within the literature, neither phage has been identified as capable of lysing E. 
coli cells. Additionally, we showed that phages Lust, Greedy, phiKZ, and DMS3 can reduce E. 
coli C populations in the multispecies EPM biofilm community. Our study clearly shows that 
phage treatment of heterogenous biofilms does not only affect the species in which it is capable 
of lysing. This provides direct evidence that phages can inhibit bacterial growth or induce lysis 
without successful infection. 
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Future work in phage remediation should consider the entire microbial population at 
stake rather than focusing solely on the most problematic bacterial species. This is especially true 
for phage therapy of human infections, as maintaining a “normal” microflora is critical for 
human health. Phage treatment has the potential to disrupt beneficial microbes that could lead to 
unintended consequences. Nevertheless, phage therapy has significant potential to improve 
human health and combat infections including CAUTIs, particularly given the increase in 
antibiotic-resistant bacteria. 
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